Presidential Speculation

Showing 276 articles
Business

C4 Therapeutics: Can Its Protein-Degrading Tech Ignite a Biotech Rally?

Amid a challenging market for biotech, C4 Therapeutics (NASDAQ: CCCC) is drawing investor attention with its targeted protein degradation platform. Backed by industry giants and focused on niche cancers, the clinical-stage company presents a high-risk, high-reward proposition. We examine the bull case and the road ahead.

Business

Ziff Davis: A Deep-Value Play or a Digital Media Trap?

Ziff Davis (ZD) shares are attracting value investors with a seemingly cheap valuation and potential asset sales. However, underlying concerns about revenue quality, customer churn, and existential threats from AI-driven search shifts paint a more complex picture for the digital media conglomerate.